Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women
Peptonic Medical AB (publ) ("Peptonic") announces that the United States Patent and Trademark Office ("USPTO") has granted patent (16238.0043U1) for the treatment and prevention of vaginal yeast infections among women. The patent, valid until 2041, represents a significant progress for Peptonic in enabling women to independently manage their intimate health. In a clinical study, good treatment results have been demonstrated in a limited group of women.The patent is based on Peptonic's clinically proven gel base which has been adapted to target candida albicans, the most common cause of
According to the updated schedule, the annual outage of Olkiluoto 3 ends on April 28.The reason for the additional eight days is the new faults found during the outage and technical problems with inspection equipment. The annual outage of OL3 started on March 2. Approximately 1,100 external professionals are involved in the outage. Olkiluoto 1 and Olkiluoto 2 are normally producing electricity with a total capacity of about 1,780 MW.
Mölnlycke Health Care signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.Gothenburg 12 April 2024: Mölnlycke Health Care, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturizing solutions.
Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of